

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>Asarpota Rajesh</u> _____ (Last) (First) (Middle) C/O MARAVAI LIFESCIENCES HOLDINGS, INC. 10770 WATERIDGE CIRCLE, SUITE 200 _____ (Street) SAN DIEGO CA 92121 _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) Other (specify below) Chief Financial Officer
	3. Date of Earliest Transaction (Month/Day/Year) 06/30/2025	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Class A Common Stock	06/30/2025		A		500,000	A	(1)	500,000	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Employee Stock Option (Right to Buy)	\$2.41	06/30/2025		A		333,333		(2)	06/30/2035	Class A Common Stock	333,333	\$0	333,333	D	
Performance Stock Units	(3)	06/30/2025		A		750,000		(3)	07/30/2028	Class A Common Stock	750,000	\$0	750,000	D	

**Explanation of Responses:**

- Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan (the "Omnibus Incentive Plan"). Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs vest over a three-year period, with one-third of the RSUs vesting on the first anniversary of the grant date and the remaining two-thirds of the RSUs vesting in 24 substantially equal monthly installments, subject to the Reporting Person's continued employment with the Issuer (except as otherwise provided in connection with certain circumstances as set forth in the award agreement).
- Represents options awarded under the Omnibus Incentive Plan. These options vest over a three-year period, with one-third of the options vesting on the first anniversary of the grant date and the remaining two-thirds of the options vesting in 24 substantially equal monthly installments, subject to the Reporting Person's continued employment with the Issuer (except as otherwise provided in connection with certain circumstances as set forth in the award agreement).
- Represents performance-based restricted stock units ("PSUs") awarded under the Omnibus Incentive Plan. Each PSU represents the contingent right to receive one share of Class A Common Stock of the Issuer. The PSUs will vest if and to the extent the volume-weighted average price of a share of the Class A Common Stock of the Issuer equals or exceeds certain thresholds for the 30 consecutive trading days immediately preceding the third anniversary of the grant date, subject to the Reporting Person's continued employment with the Issuer (except as otherwise provided in connection with certain circumstances as set forth in the award agreement).

**Remarks:**

/s/ Kurt Oreshack, by power of attorney for Rajesh Asarpota 06/30/2025  
 \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.